Revolution Medicines Inc (RVMD) — 13F Filings Explorer (Q2 2026)

RVMD ranks #780 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

RVMD is a top-conviction position for Nextech Invest Ltd. — at 67.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in RVMD belongs to BlackRock, Inc., but the position matters far more to Nextech Invest Ltd., who has 67.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its RVMD position for two straight quarters, increasing it by $1.9B to reach $2.6B today.

General Atlantic, L.p. has trimmed its RVMD position for two straight quarters, cutting it by $157.0M while still holding $67.0M.

RVMD is down 6% today, but institutions show net buying of $9.7B this quarter — a divergence between today's price move and the underlying institutional flow.

RVMD reported a net loss of $1.8B over the trailing twelve months.

• Not yet profitable — net loss of $1.8B over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$812.1M to -$1.8B
• Operating cash flow was negative, using $897.7M in cash
• Current ratio of 7.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.44x equity — within a conventional range